Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV? (original) (raw)

Injectable contraceptives are the most widely used method of contraception in sub-Saharan Africa among married or in-union women aged 15-44 [1]. Injectable contraceptive use grew more quickly than use of any other contraceptive method between 1994 and 2015: from 2% to 7% of the share of all contraceptive use (among married or in-union women) worldwide, and from 17% to 38% of the share of all contraceptive use in sub-Saharan Africa [1]. Injectables are quick to administer, highly effective, do not require daily user action, and can be used clandestinely [2]. Like all contraceptive methods, injectables can empower women and couples to achieve their reproductive goals, reduce unintended pregnancy, and prevent maternal morbidity and mortality [3]. Concerning observational data suggest that women who use the most common type of injectable contraception, depot medroxyprogesterone acetate (DMPA), may be at increased risk of HIV acquisition compared to women not using hormonal contraception [4]. In March 2017, the World Health Organization modified the Medical Eligibility Criteria for Contraceptive Use to indicate that women at high risk of HIV acquisition may use progestin

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact